Geoffrey B Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7076331/publications.pdf

Version: 2024-02-01

99 papers

4,814 citations

172386 29 h-index 98753 67 g-index

99 all docs 99 docs citations 99 times ranked 5768 citing authors

#	Article	IF	CITATIONS
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 4. Journal of Immunology, 2002, 168, 5233-5239.	0.4	605
3	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	3.0	304
4	Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 4. Journal of Immunology, 2004, 172, 20-24.	0.4	220
5	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, 1247-1262.	1.9	175
6	Activation of Mammalian Toll-like Receptors by Endogenous Agonists. Critical Reviews in Immunology, 2003, 23, 15-44.	1.0	146
7	Percutaneous Cryoablation of Musculoskeletal Oligometastatic Disease for Complete Remission. Journal of Vascular and Interventional Radiology, 2013, 24, 207-213.	0.2	133
8	Conditional signaling by Tollâ€like receptor 4. FASEB Journal, 2005, 19, 1-16.	0.2	100
9	Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiology, 2010, 39, 175-182.	1.2	97
10	Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends in Immunology, 2003, 24, 19-24.	2.9	96
11	Role of 18F-FDG PET/CT in the diagnosis of cardiovascular implantable electronic device infections: A meta-analysis. Journal of Nuclear Cardiology, 2019, 26, 958-970.	1.4	84
12	Structural and Functional Imaging in Parkinsonian Syndromes. Radiographics, 2014, 34, 1273-1292.	1.4	74
13	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1267.	3.0	66
14	A genetic basis for the "Adonis―phenotype of low adiposity and strong bones. FASEB Journal, 2004, 18, 1282-1284.	0.2	64
15	Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiology, 2016, 45, 1097-1105.	1.2	62
16	Clinical PET/MRI: 2018 Update. American Journal of Roentgenology, 2018, 211, 295-313.	1.0	59
17	The Added Value of ¹⁸ F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma. Journal of Nuclear Medicine, 2012, 53, 1200-1206.	2.8	52
18	Pulmonary Nodule Characterization, Including Computer Analysis and Quantitative Features. Journal of Thoracic Imaging, 2015, 30, 139-156.	0.8	50

#	Article	IF	Citations
19	Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1069-1071.	2.5	46
20	¹⁸ F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. Journal of Nuclear Medicine, 2018, 59, 774-779.	2.8	46
21	Endobronchial Ultrasound and Lymphoproliferative Disorders: A Retrospective Study. Annals of Thoracic Surgery, 2012, 94, 1830-1834.	0.7	45
22	Malignant Involvement of the Peripheral Nervous System in Patients with Cancer: Multimodality Imaging and Pathologic Correlation. Radiographics, 2014, 34, 1987-2007.	1.4	44
23	Biphenotypic hepatic tumors: imaging findings and review of literature. Abdominal Imaging, 2015, 40, 2293-2305.	2.0	43
24	¹¹ C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. Radiographics, 2016, 36, 279-292.	1.4	40
25	Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. American Journal of Roentgenology, 2021, 217, 730-740.	1.0	39
26	Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. Abdominal Radiology, 2016, 41, 2061-2077.	1.0	37
27	Toll-like receptor-4 and allograft responses. Transplantation, 2004, 77, 475-477.	0.5	34
28	Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdominal Radiology, 2017, 42, 1374-1392.	1.0	32
29	Frequency and Characteristics of Nodal and Deltoid FDG and ¹¹ C-Choline Uptake on PET Performed After COVID-19 Vaccination. American Journal of Roentgenology, 2021, 217, 1206-1216.	1.0	30
30	New insight into the pathogenesis of sepsis and the sepsis syndrome. Surgery, 2005, 137, 393-395.	1.0	29
31	¹¹ C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas. American Journal of Roentgenology, 2018, 210, 418-422.	1.0	28
32	Current Concepts in MRI of Focal and Diffuse Malignancy of Bone Marrow. Seminars in Musculoskeletal Radiology, 2013, 17, 137-144.	0.4	26
33	Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive ⟨sup⟩99m⟨/sup⟩ Technetium–Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, .	1.3	25
34	First PET Imaging Studies With ⁶³ Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Molecular Imaging, 2016, 15, 153601211667379.	0.7	22
35	Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. European Radiology, 2019, 29, 1684-1692.	2.3	22
36	How We Do It: A Multidisciplinary Approach to ¹⁷⁷ Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology, 2021, 298, 261-274.	3.6	21

#	Article	IF	Citations
37	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6376-6383.	3.2	21
38	ACR Appropriateness Criteria $\hat{A}^{\text{@}}$ Suspected Pulmonary Hypertension. Journal of the American College of Radiology, 2017, 14, S350-S361.	0.9	18
39	ACR Appropriateness Criteria® Lung Cancer Screening. Journal of the American College of Radiology, 2018, 15, S341-S346.	0.9	18
40	ACR Appropriateness Criteria® Rib Fractures. Journal of the American College of Radiology, 2019, 16, S227-S234.	0.9	17
41	Multimodality Imaging of Neurodegenerative Processes: Part 1, The Basics and Common Dementias. American Journal of Roentgenology, 2016, 207, 871-882.	1.0	15
42	Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology and Hepatology, 2019, 4, 559-570.	3.7	15
43	ACR Appropriateness Criteria \hat{A}^{\otimes} Acute RespiratoryÂlllness in Immunocompromised Patients. Journal of the American College of Radiology, 2019, 16, S331-S339.	0.9	15
44	Accuracy of ¹⁸ F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 1511-1516.	2.8	15
45	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Gaâ€PSMAâ€11 PET Using Cyclotronâ€Produced 68Ga. Hepatology Communications, 2022, 6, 1172-1185.	2.0	15
46	Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Advances in Experimental Medicine and Biology, 2015, 865, 123-140.	0.8	14
47	Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic EpithelialÂTumors. Journal of Thoracic Oncology, 2017, 12, 354-367.	0.5	14
48	Benign fibrous dysplasia on [11C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Annals of Nuclear Medicine, 2012, 26, 599-602.	1.2	13
49	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using ¹¹ C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. Journal of Urology, 2018, 199, 726-733.	0.2	13
50	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology, 2020, 20, 1115-1122.	0.5	12
51	ACR Appropriateness Criteria $\hat{A}^{\text{@}}$ Acute Respiratory Illness in Immunocompromised Patients. Journal of Thoracic Imaging, 2015, 30, W2-W5.	0.8	11
52	18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves. Clinical Nuclear Medicine, 2016, 41, e115-e117.	0.7	11
53	Spectrum of Benign Articular and Periarticular Findings at FDG PET/CT. Radiographics, 2016, 36, 824-839.	1.4	11
54	^{99m} Tc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. Journal of Nuclear Medicine Technology, 2018, 46, 368-372.	0.4	11

#	Article	IF	Citations
55	FDG PET/CT and MRI Features of Pathologically Proven Schwannomas. Clinical Nuclear Medicine, 2021, 46, 289-296.	0.7	11
56	Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 975-981.	1.4	10
57	Semiquantitative Analysis of Brain Metabolism in Patients With Paraneoplastic Neurologic Syndromes. Clinical Nuclear Medicine, 2013, 38, 241-247.	0.7	10
58	Pulmonary fibrosis in dyskeratosis congenita: report of 2 cases. Human Pathology, 2015, 46, 147-152.	1.1	10
59	99mTc-Tilmanocept Versus 99mTc-Sulfur Colloid in Lymphoscintigraphy: Sentinel Lymph Node Identification and Patient-Reported Pain. Journal of Nuclear Medicine Technology, 2019, 47, 300-304.	0.4	10
60	ACR Appropriateness Criteria \hat{A}^{\circledast} Imaging of \hat{A} Possible Tuberculosis. Journal of the American College of Radiology, 2017, 14, S160-S165.	0.9	10
61	PET/CT and PET/MRI in neuroendocrine neoplasms. Abdominal Radiology, 2022, 47, 4058-4072.	1.0	10
62	Comparison of facet joint activity on 99mTc-MDP SPECT/CT with facet joint signal change on MRI with fat suppression. Diagnostic and Interventional Radiology, 2016, 22, 277-283.	0.7	9
63	Multimodality Imaging of Neurodegenerative Processes: Part 2, Atypical Dementias. American Journal of Roentgenology, 2016, 207, 883-895.	1.0	9
64	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
65	PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker?. Seminars in Nuclear Medicine, 2020, 50, 549-561.	2.5	9
66	Effect of Patient Age, Breast Density, and Topical Anesthetic Cream on Perceived Pain with Sentinel Lymph Node Scintigraphy. Journal of Nuclear Medicine Technology, 2012, 40, 44-47.	0.4	8
67	Recent updates and developments in PET imaging of prostate cancer. Abdominal Radiology, 2020, 45, 4063-4072.	1.0	8
68	The flip-flop fungus sign: an FDG PET/CT sign of benignity. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 212-217.	1.0	8
69	ACR Appropriateness Criteria® Occupational Lung Diseases. Journal of Thoracic Imaging, 2016, 31, W1-W3.	0.8	7
70	ACR Appropriateness Criteria \hat{A}^{\circledast} Occupational Lung Diseases. Journal of the American College of Radiology, 2020, 17, S188-S197.	0.9	7
71	Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. Frontiers in Oncology, 2022, 12, 823667.	1.3	7
72	Future of Thoracic PET Scanning. Chest, 2015, 147, 25-30.	0.4	6

#	Article	IF	CITATIONS
73	Detection of <scp>ALECT</scp> 2 amyloidosis by positron emission tomography–computed tomography imaging with florbetapir. British Journal of Haematology, 2017, 177, 12-12.	1.2	6
74	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary BalloonÂAngioplasty for Chronic Pulmonary Thromboembolism. JACC: Cardiovascular Interventions, 2017, 10, 532-534.	1.1	6
75	ACR–SPR–STR Practice Parameter for the Performance of Cardiac Positron Emission Tomography - Computed Tomography (PET/CT) Imaging. Clinical Nuclear Medicine, 2017, 42, 918-927.	0.7	6
76	123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer. Clinical Nuclear Medicine, 2021, 46, e151-e153.	0.7	6
77	Radiologic and clinicopathologic characteristics of thyroid nodules with focal 68Ga-DOTATATE PET activity. Nuclear Medicine Communications, 2021, 42, 510-516.	0.5	5
78	177Lu-dotatate use in chronic kidney disease patients: A single center experience. Journal of Onco-Nephrology, 2021, 5, 162-171.	0.3	4
79	Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum?. American Journal of Hematology, 2015, 90, 462-465.	2.0	3
80	Embrace Progress. Journal of Nuclear Medicine, 2018, 59, 1169-1169.	2.8	3
81	Novel imaging techniques using ¹⁸ Fâ€florbetapir PET/MRI can guide fascicular nerve biopsy in amyloid multiple mononeuropathy. Muscle and Nerve, 2021, 63, 104-108.	1.0	3
82	A prospective trial of CT-guided percutaneous microwave ablation for lung tumors. Journal of Thoracic Disease, 2021, 14, 0-0.	0.6	3
83	Multicenter Experience of Technetium Pyrophosphate Scanning for Diagnosing TTR Cardiac Amyloid: A Revival in Nuclear Cardiology. Journal of Cardiac Failure, 2015, 21, S85.	0.7	2
84	Gastrointestinal: Multiparametric hybrid 18â€FDG PET/MRI evaluation of gastric adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1132-1132.	1.4	2
85	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, spcone.	1.9	2
86	Hydroxychloroquine-Mediated Cardiotoxicity with a False Positive 99M-Technetium Labeled Pyrophosphate Scan for Amyloidosis. Journal of Cardiac Failure, 2017, 23, S46-S47.	0.7	2
87	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Advances in Radiation Oncology, 2019, 4, 79-89.	0.6	2
88	Pulmonary nodules in patients with primary Sj \tilde{A} ¶gren's syndrome: Causes, clinico-radiologic features, and outcomes. Respiratory Medicine, 2020, 174, 106200.	1.3	2
89	A 48-Year-Old South African Woman with Rheumatoid Arthritis and Lung Nodules. Chest, 2020, 157, e151-e155.	0.4	2
90	Atypical Metastases in the Abdomen and Pelvis From Biochemically Recurrent Prostate Cancer: 11C-Choline PET/CT Imaging With Multimodality Correlation. American Journal of Roentgenology, 2021, , 1-10.	1.0	2

#	Article	IF	CITATIONS
91	Use of DOTATATE PET/CT Scan in the Diagnosis and Staging of Thymic Atypical Carcinoid Tumor in a Patient with Secondary ACTH-dependent Cushing Syndrome: Look Twice and Cut Once. World Journal of Endocrine Surgery, 2018, 10, 127-133.	0.0	2
92	Positron emission tomography objective parameters for assessment of left ventricular assist device infection using F-FDG PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 301-311.	1.0	2
93	Adapting a PET Imaging Agent for Correlative Microscopy of Meningiomas and Other Intracranial Tumors. Microscopy and Microanalysis, 2012, 18, 178-179.	0.2	1
94	AJRTeaching File: Left Neck Mass Evaluated by PET/CT. American Journal of Roentgenology, 2011, 196, WS78-WS82.	1.0	0
95	Unexpectedly Fludeoxyglucose (18F) Avid Well-Differentiated Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2015, 10, 719-720.	0.5	0
96	Pseudomyxoma Pleuri. A Rare Manifestation of an Uncommon Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1334-1335.	2.5	0
97	Utility of 18F-FDG PET/CT in Evaluation of Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases, 2017, 4, S547-S547.	0.4	O
98	Phase II Evaluation Of Stereotactic Ablative Radiotherapy (SABR) in 11C-Choline PET/CT (Cho-PET)-Identified Oligometastatic Castration-Resistant Prostate Cancer (CRPC). International Journal of Radiation Oncology Biology Physics, 2020, 108, e861.	0.4	0
99	18F-fluorodeoxyglucose positron emission tomography/ computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica. World Journal of Nuclear Medicine, 2021, 20, 90.	0.3	O